Chemotherapy Regimens for Head and Neck Cancer

Locally Advanced Head and Neck Cancer

The National Comprehensive Cancer Network recommends high-dose cisplatin (100 mg/m² every 3 weeks) with conventional fractionation radiotherapy (2.0 Gy per fraction to 70 Gy in 7 weeks) as the standard treatment for patients with locally advanced disease and good performance status (PS 0-1) (category 1) 1, 2
Alternative concurrent chemoradiotherapy options include carboplatin/5-FU (category 1) 1, 2 and cetuximab with radiotherapy (category 1), particularly for patients not medically fit for standard cisplatin-based chemoradiotherapy 1, 2

The National Comprehensive Cancer Network recommends cisplatin or carboplatin plus 5-FU with cetuximab (for non-nasopharyngeal cancer) (category 1), which has been shown to improve median survival compared to platinum/5-FU alone (10.1 vs. 7.4 months) 1, 3, 4
Cisplatin or carboplatin plus a taxane (paclitaxel or docetaxel) is also a recommended combination regimen 1, 3, 4

For patients with poor performance status (PS 2-3), less intensive regimens should be considered 3, 5
Combination regimens generally result in higher response rates but also increased toxicity compared to single agents 4, 6

Combination regimens typically double response rates compared to single agents 1, 4
Median survival with chemotherapy for metastatic disease is approximately 6 months, with 1-year survival rate around 20% 1, 4
Complete responses are associated with longer survival but are infrequent, reported more often with combination regimens 4, 6

All combined chemoradiotherapy regimens are associated with significant mucosal toxicities requiring close monitoring by an experienced team 1, 2
While combination regimens show higher response rates than single agents, they have not consistently demonstrated overall survival benefits in the metastatic setting except when cetuximab is added to platinum/5-FU 4, 6
The choice between single-agent and combination therapy should consider the patient's performance status, comorbidities, and treatment goals (symptom relief vs. survival) 6, 7

The European Society for Medical Oncology recommends TPF (Docetaxel, Cisplatin, 5-Fluorouracil) as the preferred induction regimen, showing significantly improved progression-free and overall survival compared to the older PF regimen 8

The National Comprehensive Cancer Network recommends high-dose cisplatin with conventional fractionation radiotherapy as the standard treatment for locally advanced disease, with single-agent platinum (cisplatin) recommended for patients with high-risk features after surgery (extracapsular extension and R1 resection) 8

The American Society of Clinical Oncology recommends platinum-based combinations as the standard for metastatic disease, with weekly methotrexate considered an accepted treatment for palliative treatment in recurrent disease 8
Combination chemotherapy (cisplatin, 5-fluorouracil or taxanes) produces higher response rates than single-agent methotrexate, though without demonstrated survival benefit 8

Nutritional status must be corrected and maintained throughout treatment, with dental rehabilitation indicated before radiotherapy to prevent complications 8
Evaluation of thyroid function in patients with irradiation to the neck is recommended at 1, 2, and 5 years post-treatment 8